Neoplasms, Glandular and Epithelial
Welcome,         Profile    Billing    Logout  
 287 Companies   339 Products   339 Products   208 Mechanisms of Action   11 Trials   3337 News 


«12345678910111213...6869»
  • ||||||||||  SF1126 / SignalRx
    Enrollment open:  SF1126 for Patients With Relapsed or Refractory Neuroblastoma (clinicaltrials.gov) -  Aug 17, 2017   
    P1,  N=28, Recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Apr 2014 Active, not recruiting --> Recruiting
  • ||||||||||  plerixafor / Generic mfg.
    Enrollment closed, Trial initiation date:  Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma (clinicaltrials.gov) -  Jul 28, 2017   
    P1/2,  N=30, Active, not recruiting, 
    Active, not recruiting --> Terminated | Trial primary completion date: Aug 2018 --> Apr 2017; The study was terminated early by the Sponsor due to the high rate of discontinuation of subjects unrelated to patient safety. Recruiting --> Active, not recruiting | Initiation date: Jul 2014 --> Nov 2014
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial primary completion date, Combination therapy:  BO21990: A Study of Bevacizumab (Avastin (clinicaltrials.gov) -  Jul 21, 2017   
    P3,  N=921, Completed, 
    Initiation date: Oct 2012 --> Jan 2005 | Trial primary completion date: Jul 2013 --> Dec 2011 Trial primary completion date: Mar 2012 --> Feb 2013
  • ||||||||||  Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin
    Biomarker, Trial completion:  SOPRANo: Somatuline Predictive Factors in Acromegaly and NET (clinicaltrials.gov) -  Jul 17, 2017   
    P=N/A,  N=156, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  letrozole / Generic mfg.
    Trial primary completion date:  DCIS: Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ (clinicaltrials.gov) -  Jul 13, 2017   
    P2,  N=108, Active, not recruiting, 
    Active, not recruiting --> Completed | N=36 --> 136 Trial primary completion date: Jun 2017 --> Aug 2016
  • ||||||||||  Avastin (bevacizumab) / Roche
    Enrollment change, Trial termination, Trial primary completion date:  Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence (clinicaltrials.gov) -  Jul 12, 2017   
    P1,  N=1, Terminated, 
    Active, not recruiting --> Terminated; The study did not continue to phase II due to the importance of HPV status as a prognostic factor to guide treatment decisions. N=24 --> 1 | Recruiting --> Terminated | Trial primary completion date: Oct 2017 --> Jan 2012; Investigators decision
  • ||||||||||  BMS-833923 / BMS
    Trial completion, Trial primary completion date:  Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome (clinicaltrials.gov) -  Jul 11, 2017   
    P=N/A,  N=2, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017 Active, not recruiting --> Completed | Trial primary completion date: Feb 2019 --> May 2017
  • ||||||||||  Rydapt (midostaurin) / Novartis
    Enrollment closed, Enrollment change, Trial primary completion date, Metastases:  Midostaurin (PKC412) for Locally Advanced Rectal Cancer (clinicaltrials.gov) -  Jun 21, 2017   
    P1,  N=19, Active, not recruiting, 
    N=21 --> 1 Recruiting --> Active, not recruiting | N=30 --> 19 | Trial primary completion date: Jun 2017 --> Mar 2015
  • ||||||||||  Trial completion:  CART-meso in Mesothelin Expressing Cancers (clinicaltrials.gov) -  Jun 20, 2017   
    P1,  N=19, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Oct 2017 Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy (clinicaltrials.gov) -  Jun 20, 2017   
    P2,  N=1, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | N=10 --> 1 | Trial primary completion date: Jan 2018 --> Jun 2017
  • ||||||||||  Votrient (pazopanib) / Novartis, BeiGene
    Biomarker, Trial completion, Trial primary completion date:  Neoadjuvant Pazopanib in Renal Cell Carcinoma (clinicaltrials.gov) -  Jun 14, 2017   
    P2,  N=21, Completed, 
    N=35 --> 20 | Completed --> Terminated | Trial primary completion date: Apr 2009 --> Aug 2008; The trial was discontinued early due to no confirmed partial responses. Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jan 2015 | Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jan 2015
  • ||||||||||  lomustine / Generic mfg., temozolomide / Generic mfg.
    Trial completion, Trial primary completion date, Combination therapy:  CeTeG: Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients (clinicaltrials.gov) -  Jun 14, 2017   
    P3,  N=141, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jan 2015 | Active, not recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jan 2015 Active, not recruiting --> Completed | Trial primary completion date: Nov 2015 --> Apr 2017
  • ||||||||||  Votrient (pazopanib) / Novartis, BeiGene
    Enrollment closed, Trial primary completion date, Metastases:  FLIPPER: First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma (clinicaltrials.gov) -  Jun 12, 2017   
    P4,  N=44, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Jun 2017